You are here

Global Microneedles & Needle-Free Injection Systems/Jet Injectors Market, 2019-2030

DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The "Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

Chronic clinical conditions, such as diabetes, cardiovascular disorders, certain types of neurological disorders, and cancer, are considered to be among the leading causes of death and disability across the world. The Center for Managing Chronic Disease at the University of Michigan recently reported that over 50% of the global population is suffering from some form of chronic disease.

Despite significant advances in drug/therapy development for the treatment of chronic diseases, there are several concerns related to the delivery of such therapeutics. Since most medications are developed for parenteral delivery, dosing errors and accidental needlestick injuries are some of the primary areas of concern. In fact, needle phobia is officially recognized as a medical condition by the American Psychiatric Association in its Diagnostic and Statistical Manual of Mental Disorders and is known to affect nearly 10% of the population.

The Needlestick Safety and Prevention Act, which was signed into law in the US in November 2000, encouraged the development of a variety of needleless syringes/safety syringes, such as needle-free injection systems, microneedle patches and microneedle pens. A sustained focus towards self-injection has also facilitated significant advances in drug development and administration. In fact, the self-injection devices market is characterized by the presence of a myriad of advanced and innovative drug delivery solutions, such as (in alphabetical order) autoinjectors, jet injectors, large volume wearable injectors, microneedles, pen injectors, needleless syringes and prefilled syringes.

The concept of needle free drug delivery is realized using a variety of actuation mechanisms (such as spring- or gas-powered devices) that are capable of facilitating the delivery of therapeutic interventions without the use of needles. On the other hand, microneedles are extremely minute needles (of the order of a few micrometers), which are designed to deliver drugs across the dermis. It is worth highlighting that such delivery systems are primarily based on the subcutaneous/intradermal and transdermal routes.

The field of needleless drug delivery continues to witness significant advances, in terms of innovation in drug/therapy administration (such as dose tracking and real-time updates) and the development of compatible drug formulations. As a result, several stakeholders in the healthcare industry have developed interest in this upcoming field, and have launched product development/commercialization initiatives in the recent past.

Scope of the Report

This report features an extensive study of the current landscape and the likely future opportunities associated with the needle-free injection systems and microneedles market, over the next 10-12 years. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the needle-free injection systems market, featuring a comprehensive list of device developers and analysis based on a number of parameters, such as year of establishment, company size, geographical location, current development status of various products (under development and commercialized), details on intellectual property portfolio, route of administration (subcutaneous, intramuscular, intradermal and others), type of load (solid and liquid), usability (disposable and reusable), actuation mechanism (spring-based, gas-powered and others), capacity of the device (in terms of volume of drug delivered) and target disease areas.
  • An overview of the current market landscape of microneedle devices, featuring a comprehensive list of device developers and analysis based on a number of parameters, such as year of establishment, company size, geographical location, current development status of various products (under development and commercialized), details on intellectual property portfolio, type of microneedle device (hollow, solid and dissolving), route of administration (subcutaneous, transdermal, intradermal and others), microneedle length and target disease areas.
  • A detailed product competitiveness analysis of both needle-free injection systems and microneedle devices, taking into consideration the supplier power (based on the year of establishment of developer company) and key product specifications. For needle-free injection systems, specifications, such as therapeutic area, route of administration, maximum device volume, usability, size of intellectual property portfolio, and commercial availability, were considered. For microneedles, specifications, such as therapeutic area, route of administration, length of microneedle, and size of intellectual property portfolio, were considered.
  • A list of marketed drugs/therapies and pipeline candidates that are anticipated to be developed in combination with needle free injectors and microneedles in the near future; the analysis is based on a variety of relevant parameters, such as (in alphabetical order) current status of development, dose concentration, dosing frequency, route of administration, type of dose (standard/weight dependent), expected patent expiry (relevant only for marketed drugs) and information on product sales (relevant only for marketed drugs).
  • An informed business portfolio analysis based on an attractiveness and competitiveness (AC) framework, highlighting the current worth of different types of needle-free injection systems and microneedle devices.
  • Elaborate profiles of prominent product developers engaged in this domain. Each profile features a brief overview of the company, its financial information (if available), information on its product portfolio and recent developments.
  • A case study on the role of contract manufacturing organizations within the medical device industry. It includes a brief description of the various regulatory guidelines for medical devices and highlights the challenges associated with the manufacturing of such products. In addition, it features a list of contract manufacturers that claim to offer services for drug delivery devices and their geographical landscape.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for needle-free injection systems and microneedle devices. Based on various parameters, such as number of marketed/pipeline products, existing price of devices (for commercially available products only) and estimated annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030.

For needle-free injection systems, the report also features the likely distribution of the current and forecasted opportunity across [A] different types of actuation mechanisms (spring-based, gas powered and others), [B] routes of administration (subcutaneous, intramuscular and intradermal), [C] target disease indication (infectious diseases, diabetes, pain disorders and others), [D] product usability (disposable and re-usable) and [E] key geographical regions (North America, Europe, Asia and Rest of the World).

Similarly, the projected future opportunity for microneedle devices has been analyzed across [A] various types of microneedle devices (hollow, solid and dissolving), [B] target disease indication (infectious diseases, osteoarthritis, pain disorders, cancer, and others), [C] type of intervention (vaccines, therapeutic agent and others), and [D] key geographical regions (North America, Europe, Asia and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Michael Schrader, CEO and Founder, Vaxess Technologies
  • Patrick Anquetil, CEO, Portal Instruments
  • Henry King, Market Intelligence and Business Development Manager, Innoture

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered

1 PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2 EXECUTIVE SUMMARY

3 INTRODUCTION
3.1 Chapter Overview
3.2. Conventional Parenteral Drug Delivery
3.2.1. Needlestick Injuries
3.2.2. Incidence and Cost Burden Related to Needlestick Injuries
3.3. Minimally Invasive Drug Delivery
3.3.1. Key Drivers of Minimally Invasive Drug Delivery Systems
3.3.1.1. Rising Burden of Chronic Diseases
3.3.1.2. Healthcare Cost Savings
3.3.1.3. Need for Immediate Treatment in Emergency Situations
3.3.1.4. Growing Injectable Drugs Market
3.3.1.5. Need for Improving Medication Adherence
3.4. Needle-Free Injection Technology
3.4.1. Key Components of Needle-Free Injection Systems
3.4.1.1. Injection Device
3.4.1.2. Nozzle
3.4.1.3. Pressure Source
3.4.2. Operating Mechanism
3.4.3. Classification of Injectors based on Type of Load
3.4.3.1. Powder-based Injectors
3.4.3.2. Liquid-based Injectors
3.4.3.3. Depot Projectile-based Injectors
3.4.4. Injectors based on Different Actuation Mechanisms
3.4.4.1. Spring Loaded Jet Injectors
3.4.4.2. Battery Powdered Jet Injectors
3.4.4.3. Gas Powdered Jet Injectors
3.4.4.4. Laser Powered Injectors
3.4.4.5. Lorentz Force-based Injectors
3.5. Drug Delivery through Microneedle Devices
3.5.1. Types of Microneedle Devices
3.5.2. Advantages of Microneedle Devices
3.5.3. Fabrication of Microneedle Devices
3.5.4. Operating Mechanism of Microneedle Devices
3.6. Needle-Free Injection Systems and Microneedle Devices: Unaddressed Challenges
3.7. Future of Needle-Free Injection Systems and Microneedle Devices

4 NEEDLE-FREE INJECTION SYSTEMS: MARKET OVERVIEW
4.1. Chapter Overview
4.2. Needle-Free Injection Systems: List of Developers
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size and Geographical Location
4.3. Needle-Free Injection Systems: List of Available / Under Development Devices
4.3.1. Analysis by Type of Load
4.3.2. Analysis by Route of Administration
4.3.3. Analysis by Actuation Mechanism
4.3.4. Analysis by Status of Development
4.3.5. Analysis by Patent Availability
4.4. Needle-Free Injection Systems: Additional Information
4.4.1. Analysis by Target Disease Area
4.4.2. Analysis by Device Capacity
4.4.3. Analysis by Product Usability
4.5. Needle-Free Injection Systems: Recent Partnerships (2015-2019)

5 MICRONEEDLE DEVICES: MARKET OVERVIEW
5.1. Chapter Overview
5.2. Microneedle Devices: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size and Geographical Location
5.3. Microneedle Devices: List of Available / Under Development Devices
5.3.1. Analysis by Type of Microneedle Devices
5.3.2. Analysis by Route of Administration
5.3.3. Analysis by Length of the Needle
5.3.4. Analysis by Target Disease Area
5.3.5. Analysis by Patent Availability

6 PRODUCT COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Assumptions and Key Parameters
6.4. Product Competitiveness Analysis: Needle-Free Injection Systems
6.4.1. Spring-based Needle-Free Injection Systems
6.4.2. Gas-powered Needle-Free Injection Systems
6.4.3. Other Needle-Free Injection Systems
6.5. Product Competitiveness Analysis: Microneedle Devices
6.5.1. Hollow Microneedle Devices
6.5.2. Solid Microneedle Devices
6.5.3. Dissolving Microneedle Devices
6.5.4. Other Microneedle Devices

7 COMPANY PROFILES
7.1. Chapter Overview
7.2. Inovio Pharmaceuticals
7.2.1. Company Overview
7.2.2. Product Portfolio
7.2.2.1. Iject
7.2.2.2. Vitajet
7.2.2.3. Serojet
7.2.2.4. ZetaJet
7.2.2.5. Biojector 2000
7.2.2.6. Jupiter Jet
7.2.2.7. ID PEN
7.3. Medical International Technology
7.3.1. Company Overview
7.3.2. Product Portfolio
7.3.2.1. MED-JET MBX
7.3.2.2. MED-JET H4
7.3.2.3. MED-JET H-III
7.3.2.4. Meso-Jet
7.4. D'Antonio Consultants International
7.4.1. Company Overview
7.4.2. Product Portfolio
7.4.2.1. LectraJet HS
7.4.2.2. LectraJet M3 RA
7.4.2.3. LectraJet M4 RA
7.5. Enesi Pharma
7.5.1. Company Overview
7.5.2. Product Portfolio
7.5.2.1. ImplaVax
7.6. PharmaJet
7.6.1. Company Overview
7.6.2. Product Portfolio
7.6.2.1. PharmaJet Stratis
7.6.2.2. Tropis
7.7. Inolife Sciences
7.7.1. Company Overview
7.7.2. Product Portfolio
7.7.2.1. Inojex 30
7.7.2.2. Nanojex
7.8. Valeritas
7.8.1. Company Overview
7.8.2. Product Portfolio
7.8.2.1. V-Go
7.9. NanoPass Technologies
7.9.1. Company Overview
7.9.2. Product Portfolio
7.9.2.1. MicronJet600
7.9.2.2. MicroPyramid
7.10. 3M
7.10.1. Company Overview
7.10.2. Product Portfolio
7.10.2.1. Hollow Microstructured Transdermal System
7.10.2.2. Solid Microstructured Transdermal System
7.11. Micropoint Technologies
7.11.1. Company Overview
7.11.2. Product Portfolio
7.11.2.1. Micropoint Patch
7.11.2.2. Hollow Microneedle Hub
7.12. Nemaura Pharma
7.12.1. Company Overview
7.12.2. Product Portfolio
7.12.2.1. Memspatch
7.12.2.2. Micro-Patch
7.12.2.3. Mycrolator

8 AC MATRIX
8.1. Chapter Overview
8.2. AC Matrix: An Overview
8.2.1. Strong Business Units
8.2.2. Average Business Units
8.2.3. Weak Business Units
8.3. AC Matrix: Analytical Methodology
8.4. AC Matrix: Plotting the Information
8.5. AC Matrix: Analyzing the Data
8.5.1. Strong Business Units
8.5.2. Average Business Units
8.5.3. Weak Business Units
8.6. Concluding Remarks

9 CASE STUDY: DRUG DELIVERY DEVICE CONTRACT MANUFACTURERS
9.1. Chapter Overview
9.2. Challenges Associated with Medical Device Manufacturing
9.3. Role of Contract Manufacturing Organizations in the Device Development Process
9.4. Regulatory Guidelines for Medical Devices
9.5. Drug Delivery Device: List of Contract Manufacturers
9.5.1. Analysis by Year of Establishment
9.5.2. Analysis by Company size
9.5.3. Analysis by Geographical Location
9.6. Geographical Distribution of Device Developers and Contract Service Providers

10 NEEDLE-FREE INJECTION SYSTEMS: LIKELY DRUG CANDIDATES
10.1. Chapter Overview
10.2. Marketed Drugs Candidates
10.2.1. Most Likely Candidates for Delivery via Needle-Free Injection Systems
10.2.2. Likely Candidates for Delivery via Needle-Free Injection Systems
10.2.3. Less Likely Candidates for Delivery via Needle-Free Injection Systems
10.2.4. Unlikely Candidates for Delivery via Needle-Free Injection Systems
10.3. Clinical Drug Candidates (Biologics)
10.4. Clinical Drug Candidates (Small Molecules)

11 MICRONEEDLE DEVICES: LIKELY DRUG CANDIDATES
11.1. Chapter Overview
11.2. Marketed Drugs Candidates
11.2.1. Most Likely Candidates for Delivery via Microneedle Devices
11.2.2. Likely Candidates for Delivery via Microneedle Devices
11.2.3. Less Likely Candidates for Delivery via Microneedle Devices
11.2.4. Unlikely Candidates for Delivery via Microneedle Devices
11.3. Clinical Drug Candidates (Biologics)
11.4. Clinical Drug Candidates (Small Molecules)

12 MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Needle-Free Injection Systems Market, 2019-2030
12.4. Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2019-2030
12.5. Global Needle-Free Injection Systems Market: Distribution by Route of Administration, 2019-2030
12.6. Global Needle-Free Injection Systems Market: Distribution by Target Disease Indication, 2019-2030
12.7. Global Needle-Free Injection Systems Market: Distribution by Product Usability, 2019-2030
12.8. Global Needle-Free Injection Systems Market: Distribution by Regions, 2019-2030
12.8.1 Needle-Free Injection Systems Market in North America, 2019-2030
12.8.1.1. Needle-Free Injection Systems Market in North America: Distribution by Actuation Mechanism, 2019-2030
12.8.1.2. Needle-Free Injection Systems Market in North America: Distribution by Route of Administration, 2019-2030
12.8.1.3. Needle-Free Injection Systems Market in North America: Distribution by Target Disease Indication, 2019-2030
12.8.1.4. Needle-Free Injection Systems Market in North America: Distribution by Product Usability, 2019-2030
12.8.2. Needle-Free Injection Systems Market in Europe, 2019-2030
12.8.3. Needle-Free Injection Systems Market in Asia, 2019-2030
12.8.4. Needle-Free Injection Systems Market in Rest of the World, 2019-2030
12.9. Global Microneedle Devices Market, 2019-2030
12.10. Global Microneedle Devices Market: Distribution by Type of Microneedle, 2019-2030
12.11. Global Microneedle Devices Market: Distribution by Target Disease Indication, 2019- 2030
12.12. Global Microneedle Devices Market: Distribution by Type of Intervention, 2019-2030
12.13. Global Microneedle Devices Market: Distribution by Regions, 2019-2030

13 INTERVIEW TRANSCRIPTS
13.1. Chapter Overview
13.2. Vaxess Technologies
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Michael Schrader, CEO and Founder
13.3. Portal Instruments
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Patrick Anquetil, CEO
13.3. Innoture
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Henry King, Market Intelligence and Business Development Manager

14 CONCLUDING REMARKS

15 APPENDIX 1: TABULATED DATA

16 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

  • 3M
  • AbbVie
  • AbGenomics
  • Ablynx
  • ABO Pharmaceuticals
  • Acceleron Pharma
  • Actavis Pharma
  • Activa Brand Products
  • ADC Therapeutics
  • AdminMed
  • Adrenomed
  • Aduro Biotech
  • Advaxis
  • Aeglea BioTherapeutics
  • Affibody
  • Agenus
  • AgonOx
  • Aijex Pharma International
  • AIM ImmunoTech
  • Akesobio Australia
  • AKRA DERMOJET
  • Alder BioPharmaceuticals
  • Alector
  • Alexion Pharmaceuticals
  • Alkahest
  • Alkermes
  • Allakos
  • Allergan
  • Allozyne
  • Alnylam Pharmaceuticals
  • AlphaCore Pharma
  • Altor BioScience
  • Ambrx
  • amcure
  • American Medical Systems
  • AMETEK Engineered Medical Components
  • Amgen
  • Amicus Therapeutics
  • Amphivena Therapeutics
  • Amplyx Pharmaceuticals
  • Amsino
  • Anesiva
  • Angiochem
  • Antares Pharma
  • Antaros Medical
  • Apex Medical Technologies
  • Apogee Technology
  • Aprea Therapeutics
  • Aptevo Therapeutics
  • argenx
  • Argos Therapeutics
  • ArmaGen
  • ARMO BioSciences
  • Aronora
  • Asklepion Pharmaceuticals
  • Astellas Pharma
  • AstraZeneca
  • Atridia
  • Atrion
  • Australasian Medical & Scientific
  • Avant Medical
  • AVEO Oncology
  • Axon Neuroscience
  • B&A Health
  • Basilea Pharmaceutica
  • Baxter International
  • Bayer HealthCare
  • Bayhill Therapeutics
  • Becton Dickinson
  • BeiGene
  • Beijing Dongfang Biotech
  • Beijing QS Medical Technology
  • Berg
  • BioArctic Neuroscience
  • BIOCAD
  • BIOCORP
  • Biogen
  • BioIntegrator
  • Bioject Medical Technologies
  • BioMarin Pharmaceutical
  • Biomedical Advanced Research and Development Authority
  • Biomerics
  • Bioniz Therapeutics
  • BioNTech
  • Bio-Path Holdings
  • BioSerenTach
  • Biotest
  • Biotest Pharmaceuticals
  • Bio-Thera Solutions
  • BioValve Technologies
  • Birla Institute of Technology and Science
  • Boehringer Ingelheim
  • Boston Pharmaceuticals
  • Bristol-Myers Squibb
  • Calando Pharmaceuticals
  • CANbridge Life Sciences
  • Cancer Advances
  • Canon Virginia
  • Cara Therapeutics
  • Carclo
  • Caretek Medical
  • Catalyst Biosciences
  • Celgene
  • Celldex Therapeutics
  • CEL-SCI
  • Children's Hospital of Eastern Ontario Research Institute
  • Chimerix
  • Chiron
  • CHO Pharma
  • Chugai Pharmaceuticals
  • Circadian Technologies
  • Cirtec Medical
  • Clearside Biomedical
  • Cleveland BioLabs
  • Conjupro Biotherapeutics
  • Consort Medical
  • Contract Medical International
  • ContraFect
  • Corium International
  • Cour Pharmaceuticals
  • Covestro
  • Crossject
  • CSL Behring
  • CSPC ZhongQi Pharmaceutical Technology
  • CStone Pharmaceuticals
  • CureTech
  • CytoDyn
  • Daiichi Sankyo
  • Sumitomo Dainippon Pharma
  • D'Antonio Consultants International
  • Debiotech
  • Dekkun
  • Delta-Fly Pharma
  • Denderon
  • Desitin Pharma
  • Diabetes Management International
  • DiaMedica Therapeutics
  • Diamyd Medical
  • Doctor Pack
  • Donatelle
  • DSM
  • Eastek International
  • EG-GILERO
  • Eisai
  • Eli Lilly
  • Elusys Therapeutics
  • EMD Serono
  • Emergent BioSolutions
  • Emory University
  • Empower Clinics
  • Endocyte
  • Enesi Pharma
  • EnGeneIC
  • EpicentRx
  • European Pharma Group
  • Europlaz Technologies
  • Evergreen Research
  • F2G
  • Fabrico Medical
  • Felton International
  • Ferring Pharmaceuticals
  • FFF Enterprises
  • FibroGen
  • Five Prime Therapeutics
  • Flex
  • FluGen
  • Forefront Medical Technology
  • Freudenberg Medical
  • FUJIFILM Pharmaceuticals
  • Galaxy Biotech
  • Galena Biopharma
  • Genentech
  • GENERON
  • GeneScience Pharmaceuticals
  • Genexine
  • Genzyme
  • Georgia Institute of Technology
  • GeoVax
  • Gerresheimer
  • Gilead Sciences
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Glide Technologies
  • Gliknik
  • Guangzhou Cellprotek Pharmaceutical
  • GW Plastics
  • H&T Presspart
  • HAL Allergy
  • Halozyme Therapeutics
  • Hanmi Pharmaceutical
  • Haywood Vocational Opportunities
  • Hoffmann-La Roche
  • Huabo Biopharm
  • IEC Electronics
  • ImClone Systems
  • Immatics Biotechnologies
  • Immune Response BioPharma
  • ImmunGene
  • Immunocore
  • ImmunoFrontier
  • ImmunoGen
  • Immunomedics
  • Immunotope
  • Immunovaccine
  • ImmuPatch
  • Implicit Bioscience
  • Incuron
  • Incyte
  • INCYTO
  • Injex
  • Innate Pharma
  • Innoture Medical Technology
  • Innovent Biologics
  • Inolife Sciences
  • Inovio Pharmaceuticals
  • Integer
  • Interplex
  • iNtRON Biotechnology
  • Inzign
  • IO Biotech
  • Ionis Pharmaceuticals
  • Ipsen
  • ISU ABXIS
  • Jabil
  • Janssen Pharmaceuticals
  • Jerini
  • JHL Biotech
  • Jiangsu Hengrui Medicine
  • Jiangsu T-Mab Biopharma
  • Johnson & Johnson
  • Jounce Therapeutics
  • Julphar
  • KaloBios Pharmaceuticals
  • KeyBioscience
  • Kiniska Pharmaceuticals
  • Kissei Pharmaceutical
  • Kura Oncology
  • Kyowa Hakko Kirin
  • Lenis Medicals
  • LEO Pharma
  • Levicept
  • Life Science Pharmaceuticals
  • LTS
  • Lundbeck
  • M&M Qualtech
  • MabVax Therapeutics
  • Mack Molding
  • MacroGenics
  • Mada Medical Products
  • Marathon Pharmaceuticals
  • McGowan Institute for Regenerative Medicine
  • McKesson and Moore Medical
  • Medical International Technology
  • MedImmune
  • MedRx
  • Menarini Group
  • Merck
  • Mereo BioPharma
  • Meridian Medical Technologies
  • Merrimack Pharmaceuticals
  • Mersana Therapeutics
  • Merus
  • Merz Pharma
  • Microdermics
  • Micron Biomedical
  • Micropoint Technologies
  • Midwest Interventional Systems
  • Mika Medical
  • Millennium Pharmaceuticals
  • MiNA Therapeutics
  • miRagen Therapeutics
  • Mitsubishi Tanabe Pharma
  • Moderna Therapeutics
  • Modulus
  • Molecular Partners
  • Molecular Templates
  • MolMed
  • MorphoSys
  • Morphotek
  • Movi SpA
  • Mundipharma
  • National Association of Convenience Stores
  • Namaste Technologies
  • NanoPass Technologies
  • NantBioScience
  • Nanyang Technological University
  • Natech Plastics
  • National University of Singapore
  • Naurex
  • Navidea Biopharmaceuticals
  • Nemaura Pharma
  • Nemera
  • Neogenix Oncology
  • Neon Therapeutics
  • Neotech Medical
  • Nexeon MedSystems
  • Nordic Bioscience
  • Northern Biologics
  • Novartis
  • NovInject
  • Novo Nordisk
  • OBI Pharma
  • Occam Design
  • Octapharma
  • Omeros
  • Oncology Venture
  • OncoMed Pharmaceuticals
  • OncoPep
  • Oncopeptides
  • Oncternal Therapeutics
  • Oncurious
  • Optimer Biotechnology
  • OSE Immunotherapeutics
  • Otsuka Pharmaceutical
  • P3 Medical
  • Paion UK
  • Paramit
  • PATH
  • Penjet
  • Peridot
  • Pfizer
  • Pharma Tech
  • PharmaJet
  • PharmaMar
  • PhaseBio Pharmaceuticals
  • Phillips-Medisize
  • Philogen
  • Phosplatin Therapeutics
  • Picofluidics
  • Pierre Fabre
  • Pique Therapeutics
  • Plastikon
  • Plexus
  • Polaris Group
  • Polyphor
  • Polyzen
  • Portal Instruments
  • Precision Engineered Products
  • Precision MicroFab
  • Preco
  • PrECOG
  • Premier Distributing
  • Prescient Therapeutics
  • Prestige BioPharma
  • Pro-Dex
  • Promedior
  • Prometheus Laboratories
  • Protalix Biotherapeutics
  • Proven Process Medical Devices
  • Providence Enterprise
  • Public Health England
  • Pulse NeedleFree Systems
  • Quality Tech Services
  • Quest PharmaTech
  • Quintessence Biosciences
  • Radius Health
  • Recro Pharma
  • Regeneron Pharmaceuticals
  • REMD Biotherapeutics
  • Resolve Therapeutics
  • rEVO Biologics
  • Rhythm Pharmaceuticals
  • Riverside Medical Packaging
  • Rchling Medical
  • Samsung Bioepis
  • SanaVita Medical
  • Sanmina
  • Sanofi
  • Santarus
  • Sanzyme
  • Savient Pharmaceuticals
  • scPharmaceuticals
  • Seattle Genetics
  • Selecta Biosciences
  • Selexys Pharmaceuticals
  • Sementis
  • Seoul National University
  • Serina Therapeutics
  • Serum Institute of India
  • Shire
  • SHL Group
  • Shreya Life Sciences
  • SkinJect
  • SMC
  • Sovrin Plastics
  • Stealth BioTherapeutics
  • Stellartech Research
  • SteriPack
  • Stevanato Group
  • Sunovion Pharmaceuticals
  • Switchback Medical
  • SymBio Pharmaceuticals
  • Symphogen
  • Synermore Biologics
  • Syntimmune
  • Syros Pharmaceuticals
  • TaiMed Biologics
  • Taiwan Liposome Company
  • Takeda Pharmaceutical
  • Tanvex BioPharma
  • Tarveda Therapeutics
  • Teva Pharmaceutical
  • TG Therapeutics
  • The National Medical Products
  • TheraJect
  • The University of Iowa
  • Tolero Pharmaceuticals
  • TRACON Pharmaceuticals
  • Translational Sciences
  • Trelleborg Sealing Solutions
  • Trend Technologies
  • TRICOR Systems
  • TRITECH BIOMED INTERNATIONAL
  • Turnstone Biologics
  • UCB
  • United BioPharma
  • University of Oxford
  • University of South Australia
  • Vaccibody
  • Vaccinex
  • Valeritas
  • Valtronic
  • VascuTech Medical
  • vasopharm BIOTECH
  • Vaupell
  • Vaxxas
  • Vaxess Technologies
  • ViiV Healthcare
  • Visterra
  • ViVO Smart Medical Devices
  • Vivozon
  • Vizient
  • Walter Reed Army Institute of Research
  • West Pharmaceutical Services
  • Westmed Medical Group
  • Wockhardt
  • World Health Organization
  • XBiotech
  • Xencor
  • Xi'an Xintong Pharmaceutical Research
  • XOMA
  • Zafgen
  • Zenius
  • Zogenix
  • Zosano Pharma

For more information about this report visit https://www.researchandmarkets.com/r/7prfmz

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/global-microneedles--needle-free-injection-systemsjet-injectors-market-2019-2030-300966225.html

SOURCE Research and Markets